# Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Acute Myeloid Leukemia

> **NCT01907815** · PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 24 (actual)

## Conditions studied

- Recurrent Adult Acute Myeloid Leukemia
- Untreated Adult Acute Myeloid Leukemia

## Interventions

- **DRUG:** Akt Inhibitor GSK2141795
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Trametinib

## Key facts

- **NCT ID:** NCT01907815
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-10
- **Primary completion:** 2016-01
- **Final completion:** 2016-01
- **Target enrollment:** 24 (ACTUAL)
- **Why stopped:** Lack of efficacy.
- **Last updated:** 2018-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01907815

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01907815, "Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01907815. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*